Global Whole Cell Cholera Vaccine

Whole Cell Cholera Vaccine Comprehensive Study by Application (Clinical Research Institutes, Hospital, Surgical Centers, Others), End User (For Adults, For Children) Players and Region - Global Market Outlook to 2024

Whole Cell Cholera Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Whole Cell Cholera Vaccine Market Overview:
The Whole Cell Cholera Vaccine market is projected to achieve significant growth in the forecast period due to increased research and development activities and rising government initiatives for the development of vaccines. Additionally, In January 2020, Emergent BioSolutions Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for the approval of the company’s single-dose oral cholera vaccine, Vaxchora (Cholera Vaccine, Live, Oral).

Growth Drivers
  • Increasing Number of Cholera Patients Worldwide
  • Growing Healthcare Infrastructure in Emerging Economies

Market Trends
  • Increased Research and Development Activities

Roadblocks
  • High Cost Associated with the Development of the Vaccine

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Rising Government Initiatives for Development of Vaccines

Challenges
  • Stringent Government Rules and Regulations


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations.
Some of the key players profiled in the report are PaxVax, Inc. (United States), Valneva SE (France), GlaxoSmithKline plc. (United Kingdom), Johnson & Johnson (United States), Merck & Co., Inc. (United States), Celldex Therapeutics, Inc. (United States), Sanofi S.A. (France), Astellas Pharma, Inc. (Japan) and Serum Institute of India Pvt.Ltd. (India). Analyst at AMA Research see United States Players to retain maximum share of Global Whole Cell Cholera Vaccine market by 2025. Considering Market by End User, the sub-segment i.e. For Adults will boost the Whole Cell Cholera Vaccine market.

In October 2018, Emergent BioSolutions Inc. has announced that it has completed its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Whole Cell Cholera Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Whole Cell Cholera Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Cholera Vaccine Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Clinical Research Institutes
  • Hospital
  • Surgical Centers
  • Others
By End User
  • For Adults
  • For Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Cholera Patients Worldwide
      • 3.2.2. Growing Healthcare Infrastructure in Emerging Economies
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Whole Cell Cholera Vaccine, by Application, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Whole Cell Cholera Vaccine (Value)
      • 5.2.1. Global Whole Cell Cholera Vaccine by: Application (Value)
        • 5.2.1.1. Clinical Research Institutes
        • 5.2.1.2. Hospital
        • 5.2.1.3. Surgical Centers
        • 5.2.1.4. Others
      • 5.2.2. Global Whole Cell Cholera Vaccine by: End User (Value)
        • 5.2.2.1. For Adults
        • 5.2.2.2. For Children
      • 5.2.3. Global Whole Cell Cholera Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Whole Cell Cholera Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. PaxVax, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Valneva SE (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Celldex Therapeutics, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A. (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Astellas Pharma, Inc. (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Serum Institute of India Pvt.Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Whole Cell Cholera Vaccine Sale, by Application, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Whole Cell Cholera Vaccine (Value)
      • 7.2.1. Global Whole Cell Cholera Vaccine by: Application (Value)
        • 7.2.1.1. Clinical Research Institutes
        • 7.2.1.2. Hospital
        • 7.2.1.3. Surgical Centers
        • 7.2.1.4. Others
      • 7.2.2. Global Whole Cell Cholera Vaccine by: End User (Value)
        • 7.2.2.1. For Adults
        • 7.2.2.2. For Children
      • 7.2.3. Global Whole Cell Cholera Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Whole Cell Cholera Vaccine: by Application(USD Million)
  • Table 2. Whole Cell Cholera Vaccine Clinical Research Institutes , by Region USD Million (2013-2018)
  • Table 3. Whole Cell Cholera Vaccine Hospital , by Region USD Million (2013-2018)
  • Table 4. Whole Cell Cholera Vaccine Surgical Centers , by Region USD Million (2013-2018)
  • Table 5. Whole Cell Cholera Vaccine Others , by Region USD Million (2013-2018)
  • Table 6. Whole Cell Cholera Vaccine: by End User(USD Million)
  • Table 7. Whole Cell Cholera Vaccine For Adults , by Region USD Million (2013-2018)
  • Table 8. Whole Cell Cholera Vaccine For Children , by Region USD Million (2013-2018)
  • Table 9. South America Whole Cell Cholera Vaccine, by Country USD Million (2013-2018)
  • Table 10. South America Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 11. South America Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 12. Brazil Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 13. Brazil Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 14. Argentina Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 15. Argentina Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 16. Rest of South America Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 17. Rest of South America Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 18. Asia Pacific Whole Cell Cholera Vaccine, by Country USD Million (2013-2018)
  • Table 19. Asia Pacific Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 20. Asia Pacific Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 21. China Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 22. China Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 23. Japan Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 24. Japan Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 25. India Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 26. India Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 27. South Korea Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 28. South Korea Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 29. Taiwan Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 30. Taiwan Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 31. Australia Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 32. Australia Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 33. Rest of Asia-Pacific Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 34. Rest of Asia-Pacific Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 35. Europe Whole Cell Cholera Vaccine, by Country USD Million (2013-2018)
  • Table 36. Europe Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 37. Europe Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 38. Germany Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 39. Germany Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 40. France Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 41. France Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 42. Italy Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 43. Italy Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 44. United Kingdom Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 45. United Kingdom Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 46. Netherlands Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 47. Netherlands Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 48. Rest of Europe Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 49. Rest of Europe Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 50. MEA Whole Cell Cholera Vaccine, by Country USD Million (2013-2018)
  • Table 51. MEA Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 52. MEA Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 53. Middle East Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 54. Middle East Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 55. Africa Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 56. Africa Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 57. North America Whole Cell Cholera Vaccine, by Country USD Million (2013-2018)
  • Table 58. North America Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 59. North America Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 60. United States Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 61. United States Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 62. Canada Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 63. Canada Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 64. Mexico Whole Cell Cholera Vaccine, by Application USD Million (2013-2018)
  • Table 65. Mexico Whole Cell Cholera Vaccine, by End User USD Million (2013-2018)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Whole Cell Cholera Vaccine: by Application(USD Million)
  • Table 76. Whole Cell Cholera Vaccine Clinical Research Institutes , by Region USD Million (2020-2025)
  • Table 77. Whole Cell Cholera Vaccine Hospital , by Region USD Million (2020-2025)
  • Table 78. Whole Cell Cholera Vaccine Surgical Centers , by Region USD Million (2020-2025)
  • Table 79. Whole Cell Cholera Vaccine Others , by Region USD Million (2020-2025)
  • Table 80. Whole Cell Cholera Vaccine: by End User(USD Million)
  • Table 81. Whole Cell Cholera Vaccine For Adults , by Region USD Million (2020-2025)
  • Table 82. Whole Cell Cholera Vaccine For Children , by Region USD Million (2020-2025)
  • Table 83. South America Whole Cell Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 84. South America Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 85. South America Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 86. Brazil Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 87. Brazil Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 88. Argentina Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 89. Argentina Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 90. Rest of South America Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 91. Rest of South America Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 92. Asia Pacific Whole Cell Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 93. Asia Pacific Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 94. Asia Pacific Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 95. China Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 96. China Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 97. Japan Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 98. Japan Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 99. India Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 100. India Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 101. South Korea Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 102. South Korea Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 103. Taiwan Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 104. Taiwan Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 105. Australia Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 106. Australia Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 107. Rest of Asia-Pacific Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 108. Rest of Asia-Pacific Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 109. Europe Whole Cell Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 110. Europe Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 111. Europe Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 112. Germany Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 113. Germany Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 114. France Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 115. France Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 116. Italy Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 117. Italy Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 118. United Kingdom Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 119. United Kingdom Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 120. Netherlands Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 121. Netherlands Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 122. Rest of Europe Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 123. Rest of Europe Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 124. MEA Whole Cell Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 125. MEA Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 126. MEA Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 127. Middle East Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 128. Middle East Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 129. Africa Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 130. Africa Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 131. North America Whole Cell Cholera Vaccine, by Country USD Million (2020-2025)
  • Table 132. North America Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 133. North America Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 134. United States Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 135. United States Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 136. Canada Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 137. Canada Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 138. Mexico Whole Cell Cholera Vaccine, by Application USD Million (2020-2025)
  • Table 139. Mexico Whole Cell Cholera Vaccine, by End User USD Million (2020-2025)
  • Table 140. Research Programs/Design for This Report
  • Table 141. Key Data Information from Secondary Sources
  • Table 142. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Whole Cell Cholera Vaccine: by Application USD Million (2013-2018)
  • Figure 5. Global Whole Cell Cholera Vaccine: by End User USD Million (2013-2018)
  • Figure 6. South America Whole Cell Cholera Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Whole Cell Cholera Vaccine Share (%), by Country
  • Figure 8. Europe Whole Cell Cholera Vaccine Share (%), by Country
  • Figure 9. MEA Whole Cell Cholera Vaccine Share (%), by Country
  • Figure 10. North America Whole Cell Cholera Vaccine Share (%), by Country
  • Figure 11. Global Whole Cell Cholera Vaccine share by Players 2018 (%)
  • Figure 12. Global Whole Cell Cholera Vaccine share by Players (Top 3) 2018(%)
  • Figure 13. Global Whole Cell Cholera Vaccine share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. PaxVax, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. PaxVax, Inc. (United States) Revenue: by Geography 2018
  • Figure 17. Valneva SE (France) Revenue, Net Income and Gross profit
  • Figure 18. Valneva SE (France) Revenue: by Geography 2018
  • Figure 19. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2018
  • Figure 21. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 23. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co., Inc. (United States) Revenue: by Geography 2018
  • Figure 25. Celldex Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Celldex Therapeutics, Inc. (United States) Revenue: by Geography 2018
  • Figure 27. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi S.A. (France) Revenue: by Geography 2018
  • Figure 29. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2018
  • Figure 31. Serum Institute of India Pvt.Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 32. Serum Institute of India Pvt.Ltd. (India) Revenue: by Geography 2018
  • Figure 33. Global Whole Cell Cholera Vaccine: by Application USD Million (2020-2025)
  • Figure 34. Global Whole Cell Cholera Vaccine: by End User USD Million (2020-2025)
  • Figure 35. South America Whole Cell Cholera Vaccine Share (%), by Country
  • Figure 36. Asia Pacific Whole Cell Cholera Vaccine Share (%), by Country
  • Figure 37. Europe Whole Cell Cholera Vaccine Share (%), by Country
  • Figure 38. MEA Whole Cell Cholera Vaccine Share (%), by Country
  • Figure 39. North America Whole Cell Cholera Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • PaxVax, Inc. (United States)
  • Valneva SE (France)
  • GlaxoSmithKline plc. (United Kingdom)
  • Johnson & Johnson (United States)
  • Merck & Co., Inc. (United States)
  • Celldex Therapeutics, Inc. (United States)
  • Sanofi S.A. (France)
  • Astellas Pharma, Inc. (Japan)
  • Serum Institute of India Pvt.Ltd. (India)
Select User Access Type

Key Highlights of Report


Sep 2020 241 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Whole Cell Cholera Vaccine Quantitative research analysis
Global Whole Cell Cholera Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Whole Cell Cholera Vaccine Report?

Have a Query? Click Here

Other Related Reports

Canine Flu Therapeutics Comprehensive Study by Application (Vet Clinics, Veterinary Hospitals, Animal Healthcare Facilities), Treatment Type (Vaccines, Anti-inflammatory Drugs, Antibiotics, Others) P...
$ 3500
Microbubbles/Ultrasound Contrast Agents Comprehensive Study by Type (Cardiovascular Diseases, Renal Diseases, Others), Application (Molecular Imaging, Gene Therapy, Drug Delivery, Stem Cells Delivery...
$ 3500
Hepatitis Test Solution Comprehensive Study by Disease Type (Hepatitis B, Hepatitis C, Others), Technology (ELISA, Rapid Diagnostics Test, PCR, INAAT, Others), End User (Hospitals & Diagnostics Labs,...
$ 3450
Behcets Disease Comprehensive Study by Application (Men, Women, Others), Affected body part (Mouth, Skin, Genitals, Eyes, Joints, Blood Vessels, Digestive System, Brain), Treatment (Corticosteroids ...
$ 3750
Montelukast Intermediate Comprehensive Study by Application (Asthma, Allergic rhinitis, Bronchospasm, Urticaria) Players and Region - Global Market Outlook to 2030
$ 3500
Oral Thrush Comprehensive Study by Type (Pseudomembranous, Erythematous, Hyperplastic, Others), Application (Hospitals, Clinics), Diagnosis Methods (Examination, Biopsy, Endoscopy, Others.), Treatmen...
$ 3450